The ECHELON-2 study has significantly advanced treatment approaches for systemic anaplastic large cell lymphoma (sALCL) and other CD30-expressing peripheral T-cell lymphomas (PTCL). Here, TNFRSF8 is linked to peripheral T-cell lymphoma, not otherwise specified.